| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/31/2011 | WO2011015656A3 Composition for treating hbv infection |
| 03/31/2011 | WO2011015333A3 Targeting of bone marrow neovasculature |
| 03/31/2011 | WO2011000962A3 Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means |
| 03/31/2011 | WO2010149752A3 Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease |
| 03/31/2011 | WO2010138610A3 Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease |
| 03/31/2011 | WO2010136897A3 Luxr mutants from vibrio fischeri auto induction expression systems using them |
| 03/31/2011 | WO2010134939A3 Mammalian genes involved in infection |
| 03/31/2011 | WO2010132112A3 Immunogenic compositions against tuberculosis |
| 03/31/2011 | WO2010122310A3 Nucleic acid molecule |
| 03/31/2011 | WO2010120566A3 METHODS FOR TREATING IgE-MEDIATED DISORDER |
| 03/31/2011 | WO2010114312A3 Human monoclonal antibody that specifically binds to vcam-1 and a composition for treating an inflammatory disease or a cancer comprising the same |
| 03/31/2011 | WO2010106127A3 Method for therapeutic use |
| 03/31/2011 | WO2010069331A3 Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders |
| 03/31/2011 | US20110078828 Multi epitope vaccine for poultry |
| 03/31/2011 | US20110077287 Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions |
| 03/31/2011 | US20110076323 Vaccine for alzheimer's disease |
| 03/31/2011 | US20110076317 Rapid establishment and/or termination of substantial steady-state drug delivery |
| 03/31/2011 | US20110076306 Arabinogalactan for enhancing the adaptive immune response |
| 03/31/2011 | US20110076305 Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins |
| 03/31/2011 | US20110076304 Adapter molecule for the delivery of adenovirus vectors |
| 03/31/2011 | US20110076302 Plant-derived vaccines against respiratory syncytial virus |
| 03/31/2011 | US20110076301 Antigenic protein fragments of streptococcus pneumoniae |
| 03/31/2011 | US20110076300 Hybrid Polypeptides Including Meningococcal fHBP Sequences |
| 03/31/2011 | US20110076299 Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 03/31/2011 | US20110076298 Soluble stabilized trimeric hiv env proteins and uses thereof |
| 03/31/2011 | US20110076297 Peptides for Inducing Heterosubtypic Influenza T Cell Responses |
| 03/31/2011 | US20110076296 TLR3 Agonist Compositions |
| 03/31/2011 | US20110076295 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| 03/31/2011 | US20110076294 Mixed Cell Populations For Tissue Repair And Separation Technique For Cell Processing |
| 03/31/2011 | US20110076292 Benzoxazepin pi3k inhibitor compounds and methods of use |
| 03/31/2011 | US20110076291 Benzoxepin pi3k inhibitor compounds and methods of use |
| 03/31/2011 | US20110076290 Dendritic cell vaccines for asparaginyl-beta-hydroxylase expressing tumors |
| 03/31/2011 | US20110076289 Transgenic animal model of neurodegenerative disorders |
| 03/31/2011 | US20110076288 Compositions for and Methods of Identifying Antigens |
| 03/31/2011 | US20110076287 Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| 03/31/2011 | US20110076286 Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
| 03/31/2011 | US20110076285 Methods and Compositions For Treatment of Ocular Fibrosis |
| 03/31/2011 | US20110076284 Novel Modulators |
| 03/31/2011 | US20110076283 Method for predicting and diagnosing brain tumor |
| 03/31/2011 | US20110076282 Methods of killing cells and use of same in prevention and treatment of cancer |
| 03/31/2011 | US20110076281 Bmp-1 procollagen c-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders |
| 03/31/2011 | US20110076280 Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| 03/31/2011 | US20110076279 Fully human anti-vegf antibodies and methods of using |
| 03/31/2011 | US20110076278 Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders |
| 03/31/2011 | US20110076277 Methods of identifying anti-inflammatory compounds |
| 03/31/2011 | US20110076276 Novel HIV reverse transcriptase inhibitors |
| 03/31/2011 | US20110076275 Method of Modifying Isoelectric Point of Antibody Via Amino Acid Substitution in CDR |
| 03/31/2011 | US20110076274 Materials and methods relating to a g-protein coupled receptor |
| 03/31/2011 | US20110076273 Highly Concentrated Pharmaceutical Formulations |
| 03/31/2011 | US20110076272 Therapeutic methods and compositions |
| 03/31/2011 | US20110076271 Diagnostic methods and compositions for treatment of cancer |
| 03/31/2011 | US20110076270 Therapeutic Binding Molecules |
| 03/31/2011 | US20110076269 Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid |
| 03/31/2011 | US20110076268 Antibodies against human respiratory syncytial virus (RSV) and methods of use |
| 03/31/2011 | US20110076267 Humanized antibody compositions and methods for binding lysophosphatidic acid |
| 03/31/2011 | US20110076266 Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animals |
| 03/31/2011 | US20110076265 Monoclonal antibodies having homosubtype cross-neutralization properties against influenza a viruses subtype h1 |
| 03/31/2011 | US20110076264 Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such |
| 03/31/2011 | US20110076263 Endoglin Antibodies |
| 03/31/2011 | US20110076262 Humanized anti-fgf19 antagonists and methods using same |
| 03/31/2011 | US20110076248 Immunizing compositions comprising hiv-1 proviral constructs with an inactive p6 gag tsg101 uev binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface. |
| 03/31/2011 | US20110076233 Delivery System for Cytotoxic Drugs by Bispecific Antibody Pretargeting |
| 03/31/2011 | US20110076232 Specific binding proteins and uses thereof |
| 03/31/2011 | CA2775642A1 Hyperblebbing shigella strains |
| 03/31/2011 | CA2775291A1 Methods, compositions, and kits for reducing anti-antibody responses |
| 03/31/2011 | CA2775050A1 Therapy for enteric infections |
| 03/31/2011 | CA2774946A1 Identification of antigenic peptides from multiple myeloma cells |
| 03/31/2011 | CA2773099A1 Novel modulators |
| 03/31/2011 | CA2772962A1 Method of preparing plant-derived vlps |
| 03/31/2011 | CA2772230A1 Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof |
| 03/30/2011 | EP2302391A1 Therapeutic and diagnostic uses of antibody specificity profiles in rheumatoid arthritis |
| 03/30/2011 | EP2302387A1 Therapeutic and diagnostic uses of antibody specificity profiles for insulin-dependent diabetes mellitus |
| 03/30/2011 | EP2302059A1 Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization |
| 03/30/2011 | EP2302041A1 Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
| 03/30/2011 | EP2302039A1 Virus-like particles comprising HML-2 gag polypeptide |
| 03/30/2011 | EP2302038A1 Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses |
| 03/30/2011 | EP2302033A2 Identification of virulence associated regions RD1 and RD5 enabling the development of improved vaccines of M. bovis BCG and M. microti |
| 03/30/2011 | EP2301972A1 Method to prepare immunogenic lipopeptides comprising T-helper and B-cell epitopes |
| 03/30/2011 | EP2301971A1 Antibodies that bind both BCMA and TACI |
| 03/30/2011 | EP2301970A1 Human antibodies that bind human IL-12 and methods for producing |
| 03/30/2011 | EP2301968A2 Humanized monoclonal antibody HPAM4 |
| 03/30/2011 | EP2301967A2 Single domain antibodies for nasal administration |
| 03/30/2011 | EP2301966A1 Immunoglobulin variants and uses thereof |
| 03/30/2011 | EP2301965A1 Antibodies that bind cell-associated CA 125/0722P and methods of use thereof |
| 03/30/2011 | EP2301960A2 Polymer conjugates of mutated neublastin |
| 03/30/2011 | EP2301957A2 Altered fibronectin-binding protein of staphylococcus aureus |
| 03/30/2011 | EP2301955A2 Varicella Zoster virus vaccine |
| 03/30/2011 | EP2301947A2 Secreted proteins and uses thereof |
| 03/30/2011 | EP2301629A2 Anti-interferon-alpha antibodies |
| 03/30/2011 | EP2301582A1 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| 03/30/2011 | EP2301581A1 Production and use of novel peptide-based agents for use with B1-specific antibodies |
| 03/30/2011 | EP2301580A1 Anti-VEGF antibodies |
| 03/30/2011 | EP2301579A1 Therapeutic method for reducing angiogenesis |
| 03/30/2011 | EP2301578A2 Methods for treating TWEAK-related conditions |
| 03/30/2011 | EP2301577A2 Methods for treating TWEAK-related conditions |
| 03/30/2011 | EP2301576A1 Therapeutic use of Anti-CS1 Antibodies |
| 03/30/2011 | EP2301575A1 Methods of therapy for solid tumors expressing the CD40 cell-surface antigen |
| 03/30/2011 | EP2301574A1 Virulent systemic feline calicivirus |
| 03/30/2011 | EP2301573A1 Anti-cancer and anti-infectious disease compositions and methods for using same |
| 03/30/2011 | EP2301572A1 Cell-derived viral vaccines with low levels of residual cell DNA |